Daiichi Sankyo and AstraZeneca have secured a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Datroway, or datopotamab deruxtecan, as a first-line monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy. The proposed indication, which remains subject to a final European Commission decision, is supported by the Phase 3 TROPION-Breast02 trial showing improvements in overall survival and progression-free survival over investigator-selected chemotherapy.
The importance of the recommendation extends beyond the regulatory expansion of another oncology medicine. It potentially moves a TROP2-directed antibody-drug conjugate into the first-line setting for a patient group that has continued to depend heavily on conventional chemotherapy despite rapid advances elsewhere in breast cancer treatment.
Why Datroway’s survival benefit matters more than another progression-free survival win
TROPION-Breast02 enrolled 644 patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not considered an option. Participants were randomly assigned to receive Datroway or an investigator-selected chemotherapy regimen that could include paclitaxel, nab-paclitaxel, capecitabine, carboplatin or eribulin.
Datroway produced a median progression-free survival of 10.8 months, compared with 5.6 months for chemotherapy. The hazard ratio of 0.57 represented a 43 percent reduction in the risk of disease progression or death. Median overall survival reached 23.7 months with Datroway, compared with 18.7 months in the chemotherapy group, translating into a hazard ratio of 0.79.
The five-month difference in median overall survival gives the recommendation considerably more weight than an approval supported only by tumour response or delayed progression. Overall survival remains one of the most clinically meaningful endpoints in metastatic triple-negative breast cancer, particularly because the disease can progress quickly and subsequent treatment opportunities may be limited.
The magnitude of the progression-free survival improvement was more pronounced than the overall survival effect, which is not unusual in metastatic cancer trials where patients receive additional therapies after progression. However, the confidence interval for the overall survival hazard ratio approached the threshold of no difference, indicating that the survival benefit is statistically supported while the precise size of the long-term advantage remains less certain.
The objective response rate also favoured Datroway, reaching approximately 63 to 64 percent compared with about 30 percent for chemotherapy. This gap is potentially important for patients with a high tumour burden or rapidly developing symptoms, where achieving an early and meaningful response can influence organ function, pain and the ability to remain on treatment.
Response rates alone cannot establish that a medicine should replace an existing standard. In this case, however, the response advantage was accompanied by longer progression-free survival and overall survival, creating a more complete efficacy argument than is often seen with oncology therapies seeking an earlier treatment position.
How first-line TROP2 targeting could reshape care for patients excluded from immunotherapy
The first-line metastatic triple-negative breast cancer market is already divided by immunotherapy eligibility. Patients whose tumours express sufficient levels of PD-L1 may receive pembrolizumab combined with chemotherapy, while those who do not meet the biomarker requirement, have contraindications or cannot otherwise receive immunotherapy have fewer targeted options.
Datroway is not positioned as a direct replacement for pembrolizumab-based therapy in immunotherapy-eligible patients because TROPION-Breast02 did not test that question. Instead, the proposed indication addresses the group left outside the established immunotherapy pathway. That distinction will be important in clinical guidelines, reimbursement assessments and treatment discussions.
The trial population was broader than a simple PD-L1-negative subgroup. It included patients with PD-L1-positive tumours who could not receive immunotherapy because of previous exposure during treatment for earlier-stage disease, comorbidities or limitations on access. This makes the proposed indication clinically inclusive, but it also creates a heterogeneous population with different reasons for being classified as unsuitable for immunotherapy.
A patient unable to receive immunotherapy because of an autoimmune condition may not carry the same prognosis or treatment history as a patient whose tumour lacks the required PD-L1 expression. Patients previously exposed to immunotherapy in an early-stage setting may present another distinct biological and clinical group. Real-world evidence will therefore be needed to determine whether Datroway produces comparable outcomes across these categories.
The recommendation also represents a broader change in how antibody-drug conjugates are being developed. These medicines were initially used primarily after several previous therapies, when tumours had become resistant to standard regimens. Moving Datroway into first-line treatment indicates growing confidence that targeted delivery of a potent cytotoxic payload can challenge chemotherapy at the beginning of metastatic care rather than being reserved for later disease.
Why the TROPION-Breast02 design supports approval but leaves real-world questions
TROPION-Breast02 was a global, randomised Phase 3 study with overall survival and blinded independent central review of progression-free survival as dual primary endpoints. Independent radiological assessment reduces the risk that knowledge of assigned treatment could influence progression decisions in an open-label study, while overall survival is less vulnerable to subjective interpretation.
The chemotherapy control arm also reflected several treatments used in routine practice rather than relying on a single comparator. This strengthens the relevance of the trial for healthcare systems where first-line chemotherapy selection varies according to previous treatment, disease-free interval, organ function, neuropathy risk and physician preference.
However, investigator-selected chemotherapy introduces variation within the control group. More than half of the patients receiving chemotherapy were treated with nab-paclitaxel, while smaller proportions received paclitaxel, eribulin, carboplatin or capecitabine. Outcomes for the overall control group may not precisely represent the performance of every individual regimen used across European centres.
The study included patients with challenging disease characteristics, including stable brain metastases and recurrent disease with short disease-free intervals. That inclusion improves the clinical relevance of the findings because metastatic triple-negative breast cancer frequently involves aggressive recurrence and central nervous system disease.
Important exclusions remain. Patients with ongoing interstitial lung disease, previous pneumonitis requiring steroid treatment or clinically significant corneal disease were not represented in the pivotal population. Clinicians will consequently have limited evidence for using Datroway in patients who already carry some of the conditions most relevant to its safety profile.
The open-label design may also have influenced treatment discontinuation, supportive care and patient-reported assessments, even though the principal progression endpoint was independently reviewed. The survival result is reassuring, but longer observation will still be valuable for understanding treatment sequencing, late toxicities and whether certain clinical subgroups derive a larger or smaller benefit.
How Datroway compares with pembrolizumab combinations, Trodelvy and chemotherapy
Datroway’s most immediate competitor in the proposed population remains chemotherapy rather than another first-line targeted therapy. Pembrolizumab combined with chemotherapy is established in Europe for previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 expression measured by a combined positive score of at least 10. Patients who meet that requirement and can tolerate immunotherapy remain outside the population tested in TROPION-Breast02.
This prevents a simple conclusion that Datroway is the preferred first-line treatment for all metastatic triple-negative breast cancer. The more defensible interpretation is that it could become the leading non-immunotherapy option for patients who would otherwise begin treatment with chemotherapy alone.
Trodelvy, or sacituzumab govitecan, is another TROP2-directed antibody-drug conjugate authorised in Europe for unresectable or metastatic triple-negative breast cancer. Its current European indication applies after two or more previous systemic therapies, including at least one for advanced disease. Datroway would therefore occupy an earlier and different position if the European Commission approves the proposed extension.
Direct comparison between the two antibody-drug conjugates is not possible from separate trials. Both target TROP2 and deliver topoisomerase I inhibitor payloads, but they differ in antibody structure, linker technology, payload, drug-to-antibody characteristics, dosing schedules and toxicity patterns. Cross-trial comparisons would also be distorted by major differences in prior treatment and disease stage.
The competitive question is likely to shift toward sequencing. Patients receiving Datroway first line may later become candidates for Trodelvy, platinum chemotherapy, PARP inhibition in appropriate biomarker-defined cases or other emerging antibody-drug conjugates. Evidence remains limited on whether sequential use of two TROP2-directed therapies will provide sufficient benefit after resistance to the first agent.
Resistance could arise through reduced TROP2 expression, impaired internalisation, altered linker processing, drug efflux or reduced sensitivity to topoisomerase I inhibition. Understanding these mechanisms will become increasingly important as multiple antibody-drug conjugates move into earlier breast cancer settings.
Why stomatitis, ocular toxicity and lung injury could influence clinical adoption
Datroway’s safety profile differs meaningfully from that of conventional chemotherapy. Stomatitis, nausea, alopecia, fatigue, haematological abnormalities, dry eye and keratitis were among the commonly reported adverse reactions in TROPION-Breast02. Serious adverse reactions occurred in a minority of patients, while interstitial lung disease and pneumonitis remain high-priority risks requiring active surveillance.
Grade 3 or higher treatment-related adverse events were reported in approximately 33 percent of Datroway recipients and 29 percent of chemotherapy recipients. Treatment discontinuation caused by treatment-related adverse events was numerically lower with Datroway, suggesting that many toxicities could be managed through monitoring, supportive care, dose interruption or dose modification.
The overall percentages do not fully describe the operational challenge. Oral toxicity may require preventive mouth care and rapid intervention before symptoms become severe enough to interrupt treatment. Ocular adverse events can require baseline assessment, lubricating drops, monitoring and referral when symptoms persist or worsen.
Interstitial lung disease presents a different problem because it can be uncommon but potentially fatal. One fatal case associated with interstitial lung disease or pneumonitis was reported in the treated population described for the indication. Early recognition of cough, breathlessness, fever or radiological changes will be essential because delayed diagnosis can allow lung injury to progress.
The trial’s exclusion of patients with active or clinically significant pre-existing lung and corneal conditions means that real-world safety could differ when the treatment reaches a broader population. European pharmacovigilance data will be particularly important during the first years of use, when clinicians begin treating patients with more comorbidities than those typically enrolled in pivotal trials.
Datroway is administered intravenously once every three weeks. This schedule may be more convenient than some weekly chemotherapy regimens, but it still requires infusion capacity, trained staff and ongoing toxicity monitoring. Adoption will depend not only on efficacy but also on whether oncology centres can integrate oral, ocular and pulmonary monitoring into routine workflows.
What European reimbursement and sequencing decisions could determine next
A positive CHMP opinion is a major regulatory milestone, but it does not immediately guarantee commercial access across the European Union. The European Commission must first approve the indication, after which national and regional health technology assessment bodies will evaluate pricing, reimbursement and comparative value.
The overall survival improvement will strengthen the reimbursement case because payers generally place greater weight on survival than on response rate alone. The near doubling of median progression-free survival may also reduce the frequency of early treatment changes, hospital visits associated with progression and complications caused by uncontrolled disease.
Cost-effectiveness assessments will still need to account for the acquisition price of an antibody-drug conjugate, treatment duration, infusion requirements and the expense of managing stomatitis, ocular toxicity and possible lung injury. Datroway remained effective for longer than chemotherapy in the trial, but longer treatment exposure can increase total drug spending even when it improves outcomes.
European access may therefore develop unevenly. Larger oncology centres and healthcare systems with established antibody-drug conjugate infrastructure may adopt the treatment more rapidly, while countries with slower reimbursement negotiations or limited infusion capacity could continue relying on chemotherapy.
Manufacturing and supply will also matter if Datroway expands simultaneously across breast cancer and lung cancer indications. Antibody-drug conjugates require complex production, conjugation and quality-control systems. Daiichi Sankyo’s ability to maintain supply while AstraZeneca supports commercial expansion will be an important, although less visible, part of successful European adoption.
What clinicians and industry observers should watch after the CHMP recommendation
The most important near-term development will be the European Commission’s decision and the final wording of the product information. That documentation will define the approved patient population, warnings, dose-modification requirements and monitoring recommendations that clinicians must apply.
Attention will then move to national reimbursement, guideline placement and adoption outside specialist academic centres. The central question is whether Datroway becomes the default first-line option for most immunotherapy-ineligible patients or one of several choices selected according to lung risk, ocular history, tumour burden and previous treatment.
Further evidence will be needed in patients with active brain metastases, significant pulmonary disease and other characteristics underrepresented in TROPION-Breast02. The effectiveness of subsequent therapies after Datroway and the feasibility of using another TROP2-directed antibody-drug conjugate will also influence the long-term value of moving the drug into first line.
The positive CHMP opinion is therefore more than an incremental label expansion. Datroway has demonstrated that an antibody-drug conjugate can improve both progression-free survival and overall survival against chemotherapy in previously untreated metastatic triple-negative breast cancer when immunotherapy is not an option.
The strongest argument for adoption is the completeness of that efficacy package. The principal limitations are the heterogeneous definition of immunotherapy ineligibility, the need for structured toxicity management and the absence of evidence showing how the treatment should be sequenced with other TROP2-directed medicines.
Provided the final European authorisation and reimbursement decisions remain favourable, Datroway could remove conventional chemotherapy from its long-held default position for a substantial and underserved segment of metastatic triple-negative breast cancer. The next test will be whether the trial’s survival advantage can be reproduced safely and consistently across routine European oncology practice.
